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Abstract: Optical imaging and spectroscopy have emerged as effective 
tools for detecting malignant changes associated with oral cancer. While 
clinical studies have demonstrated high sensitivity and specificity for 
detection, current devices either interrogate a small region or can have 
reduced performance for some benign lesions. We describe a snapshot 
imaging spectrometer that combines the large field-of-view of widefield 
imaging with the diagnostic strength of spectroscopy. The portable device 
can stream RGB images at 7.2 frames per second and record both 
autofluorescence and reflectance spectral datacubes in < 1 second. We 
report initial data from normal volunteers and oral cancer patients. 
©2013 Optical Society of America 
OCIS codes: (170.0170) Medical optics and biotechnology; (170.6510) Spectroscopy, tissue 
diagnostics; (110.4234) Multispectral and hyperspectral imaging. 
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1. Introduction 
Oral cancer is a significant global health problem. In the US alone, around 40,000 people will 
be diagnosed with oral cancer and 8,000 will die from the disease this year [1,2]. More than 
one third of individuals diagnosed with oral cancer will die within five years, because it is 
typically discovered in a later stage when treatment is less effective. Unfortunately, these 
numbers have not improved for decades. Although the need for early diagnosis is clear, there 
are many factors that contribute to delay. The standard screening practice for oral cancer is 
visual inspection and palpation. During this procedure, clinicians check for abnormal lesions 
such as leukoplakia and erythroplakia, which appear as white and red patches in the oral 
cavity [3]. These lesions can be confused with benign conditions such as lichen planus, 
inflammation, and hyperkeratosis. Therefore, localized oral cancer may appear benign to a 
physician until an advanced stage. Lesions that are suspicious should be biopsied for 
histopathology, but physicians and patients are often unwilling to proceed with invasive 
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biopsies especially when the expected yield is low. Biopsies also take time to process and 
examine, adding to patient stress and prolonging the time to diagnosis. When a biopsy is 
obtained, the small tissue region being sampled may not represent the highest pathological 
grade of a heterogeneous tumor [4]. 
Screening with optical imaging and spectroscopy has the potential to improve oral cancer 
diagnostics, while also lessening time and discomfort associated with traditional procedures. 
This is accomplished through non-invasive measurements that detect morphological and 
biochemical alterations which occur during cancer progression. For example, epithelial 
cancers are associated with degradation of stromal collagen as well as increased epithelial 
metabolism [5]. These alterations can be identified within autofluorescence spectra of the 
tissue by using a point spectrometer. Cancer is also associated with angiogenesis, which can 
affect both autofluorescence and reflectance spectra. Several clinical studies have used depth-
sensitive point spectrometers to detect the associated spectral changes. One study of 46 
subjects and 119 sites found that spectral shape, intensity, and peak wavelength can be used to 
classify oral cavity lesions with 82% sensitivity and 87% specificity in a validation set [6,7]. 
Another method, called Trimodal spectroscopy, incorporates additional diffuse reflectance 
measurements, which provides information regarding tissue absorption and structure, such as 
hemoglobin concentration and stromal collagen density. Results from this technique showed 
96% sensitivity and specificity in distinguishing cancerous/dysplastic from normal tissue. In 
addition, the technique could distinguish dysplastic from cancerous tissue with a sensitivity of 
64% and a specificity of 90% [8]. However, the small sampling area of these spectroscopic 
techniques makes it is difficult to screen the entire oral cavity for disease. 
Another modality called widefield autofluorescence imaging can screen several 
centimeters of tissue at one time. When excited with blue light, normal tissue emits a pale 
blue/green autofluorescence that can be detected visually or with an image detector array. 
Dysplastic and cancerous regions with reduced autofluorescence appear dark-brown [9]. One 
such widefield autofluorescence device called the VELscope (LED Dental, Burnaby, Canada) 
is now FDA approved as an aid for oral cancer detection [10–12]. In one study, the VELscope 
identified 196 of 203 (97%) cases of severe dysplasia / carcinoma in situ (CIS) and invasive 
cancer using loss of autofluorescence, as well as 59 of 76 (78%) cases of low-grade 
(mild/moderate) dysplasia [13]. The device has also been used to delineate tumor margins. In 
a 2006 study, the device showed reduced autofluorescence beyond the clinically visible tumor 
in 19 out of 20 specimens. Biopsies from margins with reduced autofluorescence revealed 
dysplasia or cancer in 32 of 36 sites (89%) [10]. While the effectiveness of widefield 
autofluorescence imaging shows potential for detection of oral cancers and delineation of 
tumor margins, acquiring additional spectral information may increase specificity when 
imaging benign lesions, especially in a low-risk screening population. 
An ideal approach for early cancer diagnostics could be to combine widefield imaging 
with spectral acquisition. This can be accomplished with spectral imaging, which is an optical 
modality that collects a full set of spatial and spectral information called a “datacube.” 
Although hyper- and multispectral imaging has been used extensively in the fields of remote 
sensing, astronomy, and food inspection, spectral imaging for cancer diagnostics is relatively 
new. Most current imaging spectrometers require a scanning mechanism to sequentially 
collect spatial and spectral data, which can be time consuming and impractical for clinical 
applications. For example, devices that employ a standard CCD coupled to a scanning liquid 
crystal tunable filter were be used to recover oxy/deoxy-hemoglobin spectra, which enabled 
imaging of vascular activity, oxygen saturation, scattering, and absorption in vivo over the 
entire tissue region [14]. These peaks cannot be distinguished using a conventional three-color 
CCD. However, the devices require long exposure times and binning for adequate light 
collection. Another clinical imaging device, built specifically for multispectral imaging of the 
oral cavity, uses motorized filter wheels for sequential acquisition. The Multispectral Digital 
Microscope obtains ten narrowband, parallel- and cross-polarized, and white-light images at 
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four exposure settings with an acquisition time of one minute [9,15,16]. However, scanning 
through spectral filters results in image misalignment. Long exposure times also cause motion 
blur that possibly reduces accuracy of spatial/spectral features in the data set. In another 
study, the authors also suggested the benefit of more spectral samples [17], because 
autofluorescence changes associated with cancer progression can be better visualized with a 
full spectrum [7]. 
In this manuscript we present a new type of clinical imaging spectrometer that captures all 
spatial and spectral data simultaneously with efficient light throughput. The device can collect 
multimodal data in autofluorescence or reflectance modes, in order to measure different 
morphological and biochemical alterations associated with cancer progression. Multimodal 
datacubes with 350 x 355 spatial x 41 spectral samples were acquired with a recording time of 
< 1 second. Therefore, the device captures >200 thousand spectra per acquisition. We assess 
the diagnostic value of the multimodal device with a pilot study of eleven oral cancer patients. 
Spectral images and spectra are shown for several normal and abnormal regions and 
preliminary analysis is presented. 
2. Methods 
2.1 Instrumentation 
We built a multimodal snapshot imaging spectrometer based on a research instrument called 
the Image Mapping Spectrometer (IMS). The IMS has been used for live cell microscopy 
[18], animal imaging [19], ophthalmology [20], and endoscopy [21]. The study shown here is 
the first multi-patient clinical trial with the device. We modified the instrument to be more 
amenable to clinical research by making it compact, portable, rugged, and user-friendly. 
Briefly, we mounted the device to a portable tripod, attached a camera lens for wide-field 
imaging, and developed software-controlled illumination and acquisition (see Fig. 1). 
 
Fig. 1. The snapshot spectral imager has LEDs for autofluorescence (AF) and reflectance (WL) 
imaging. It collects 350 x 350 spatial x 41 spectral points simultaneously and is controlled with 
LabVIEW on a laptop computer. 
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Although the operational principle and performance of the IMS was previously described 
[22,23], we provide a short list of specifications in Table 1. The device is capable of recording 
350 x 355 spatial x 41 spectral samples simultaneously with 58% light throughput at a 
maximum rate of 7.2 frames per second (FPS). A 3X zoom lens was attached to the existing 
distal optics of the IMS to obtain a FOV of 3 – 5 cm within the oral cavity. The spectral range 
was limited to 471 - 667 nm by a bandpass filter placed behind the camera lens. These 
wavelengths were selected because they contain spectral peaks of autofluorescence emission 
(i.e. collagen, NADH, FAD) and reflectance features (i.e. oxy- and deoxy-hemoglobin). To 
provide reflectance and autofluorescence excitation of the tissue, we used two high-power 
light emitting diodes (LEDs). A 10 W 405 nm (blue) LED was selected for autofluorescence 
excitation, as this wavelength has been shown to significantly increase contrast of emission 
from normal/abnormal lesions; also, this wavelength is blocked by the bandpass filter [9]. A 5 
W broadband white LED was selected for reflectance imaging. The LED intensities were 
controlled with a USB data acquisition device. 
The illumination system, camera acquisition, and image display were synchronized using 
a custom LabVIEW interface. Shown in Fig. 1, this program allows the user to switch 
between autofluorescence and reflectance imaging modes, adjust LED intensity, change 
display gain and color balance, and save datacubes. A real-time RGB representation of the 
datacube is also displayed. To match image display rate with the 7.2 FPS frame rate of the 
camera, we chose to display a streaming color representation of the datacube using only three 
spectral images (corresponding to red, green, and blue color channels). However, the entire 
datacube is recorded when the user saves an image. The complete acquisition sequence (1) 
records the reflectance datacube and RGB image, (2) turns the white LED off and blue LED 
on, (3) adjusts camera exposure and gain, and (4) records the autofluorescence datacube and 
RGB image. 
Table 1. Specifications for the Snapshot Imaging Spectrometer 
Parameter Specification 
Field of View ~5 cm diameter 
Working Distance 10 – 20 cm (adjustable zoom lens) 
Spatial Sampling 350 x 355 pixels 
Spatial Resolution ~200 µm 
Spectral Range 471 – 667 nm 
Spectral Sampling 41 pixels 
Spectral Resolution 6 – 16 nm 
Frame Rate Up to 7.2 FPS 
Pixel Size 7.4 x 14.8 µm2 
Bit Depth 12 bit 
Blue LED 405 nm, 10 W, 5.5 mW @ tissue 
White LED broadband, 5 W, 8 mW @ tissue 
Raw data from the IMS is a single encoded camera frame that contains all spatial and 
spectral information. Data must be reconstructed into a datacube using a custom calibration 
procedure, as described in [23]. The device was also flat-field corrected in order to account 
for small defects within the optical train. Flat-fielding was performed in reflectance mode 
using a certified reflectance standard (Spectralon) and a tungsten lamp. The spectra of the 
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tungsten lamp was also recorded with a point spectrometer and used to normalize the IMS 
spectra [23]. 
2.2 Pilot clinical study design 
The device was first tested on normal volunteers at Rice University under IRB protocol 11-
218E. Images were acquired under Rice University protocol 07-62F and MD Anderson 
Cancer Center protocol 2006-0673. All tissue was illuminated in compliance with guidelines 
for UV/VIS exposure. Patients having abnormal tissue resected from the oral cavity were 
considered eligible for the study. Data was collected in vivo from consenting patients. When 
possible, data was collected from the lesions and clinically normal imaged sites, and biopsies 
were obtained from the lesion and the normal sites for pathological examination. 
3. Results 
3.1 Device characterization 
Although the imaging spectrometer was thoroughly characterized for other applications [23], 
the modified device was further evaluated for spatial resolution, color balance, excitation light 
rejection, and recording speed. Using a 1951 USAF resolution target we found the device 
could resolve 200 µm features. A Macbeth ColorChecker chart was used to assess color 
balance of true-color reflectance datacube images. Fluorescence spectra were verified with 
measurements from a fluorescence calibration standard (Rhodamine dye, 2 mg/L). Rejection 
of excitation light was verified with a quartz disc, which showed less than 1:10 fluorescence 
ratio compared to the autofluorescence of normal tissue. The time to acquire a sequence of 
reflectance and autofluorescence datacubes was also calculated. This metric is important 
because movement of the patient, clinician, or researcher during a long acquisition can cause 
motion blur or misregistration of spectral images. The device was set to capture reflectance 
and autofluorescence datacubes at 100 ms and 500 ms exposure (with 0 dB and 20 dB gain), 
respectively. It took approximately 300 ms to adjust camera exposure/gain settings and to 
change white/blue LED intensities. Therefore, the total time to record both multimodal 
spectral datacubes, consisting of 41 x 2 spectral images, was < 1 second. Spectral images 
within each datacube have > 99% coregistration [23]. 
3.2 Pilot clinical study summary 
Data are shown from 11 patients and 20 sites. Only measured sites with histopathology were 
included in the analysis. One site was excluded because of crosstalk from tooth 
autofluorescence. Table 2 summarizes the number of measurements acquired for different 
anatomical locations. Clinical impression (rendered by an experienced head and neck 
oncologic surgeon) and histopathological diagnosis (determined by an experienced head and 
neck pathologist) were determined for each site. Clinical impression fell into one of four 
categories: normal, abnormal low risk, abnormal high risk, and cancer. Histopathological 
diagnosis fell into one of five categories: normal, mild dysplasia, moderate dysplasia, severe 
dysplasia / carcinoma in situ (CIS), and invasive cancer. Any histopathologic category could 
also include hyperkeratosis, hyperplasia, and/or inflammation. Table 3 summarizes the 
clinical impression versus histopathologic diagnosis for all sites in the study. Of particular 
interest were sites where clinical impression and diagnosis did not match, because these 
indicated either clinically unsuspicious malignant lesions (false negatives) or clinically 
suspicious benign lesions (false positives). For example, three sites that appeared as low risk 
by clinical impression were found to be dysplasia or cancer by histopathology. 
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Table 2. Anatomic Sites of ROIs in the Dataset 
 
Location Tongue Buccal Fl. of Mouth Gingiva Lip Palate Total 
 
 
Sites (%) 11 (55) 1 (5) 3 (15) 3 (15) 1 (5) 1 (5) 20 (100)  
Table 3. Clinical Impression versus Histopathological Diagnosis for 24 Biopsy Sites 
 Clinical Impression  
Histopathological 
Diagnosis 





Normal 5 — — — 5 (25) 
 
Mild Dysplasia 2 — — — 2 (10) 
 
Moderate Dysplasia — 1 — — 1 (5) 
 
Severe Dysplasia/CIS — 1 1 — 2 (10) 
 
Cancer — 1 1 8 10 (50) 
 
3.3 Spectral imaging results 
Figure 2 presents example data obtained from the multimodal imaging spectrometer. Figures 
2(a) and 2(d) show true-color images obtained from the right ventral tongue, which were 
reconstructed from the reflectance and autofluorescence datacubes, respectively. The 
autofluorescence images reveal a bright blue/green emission that is consistent with the 
appearance of normal tissue obtained with standard widefield autofluorescence imaging [10]. 
Similarly, autofluorescence spectra from the site (Fig. 2(f), “normal”) exhibit a strong blue 
peak, which is consistent with measurements of normal tissue from point spectrometers [6,7]. 
Clinical impression and histology from a biopsy (white circle) confirm the normal diagnosis. 
Figures 2(b) and 2(e) show results from another site (dotted circle) in the same patient with 
clinical impression “erythroplakia, abnormal high risk” and histopathological diagnosis of 
“cancer.” Here the autofluorescence image and spectra reveal a distinct reduction of 
blue/green fluorescence (Fig. 2(f), “abnormal”). Reflectance spectra (Fig. 2(c)) contain 
characteristic hemoglobin features in the range 540 - 580 nm. The striping artifact in the 
images is caused by slight variations in the IMS’s optical train. A detailed explanation of this 
artifact and its effect on the measured spectra is provided in [23]. In brief, facet defocus 
reduces spectra resolution, but this does not affect the locations of spectral peaks. 
Figure 3 presents spectral imaging results from two precancerous sites in a single patient. 
Figures 3(a) and 3(d) show reflectance and autofluorescence results from the right anterior 
floor of mouth, which contains a region of erythroplakia. Autofluorescence imaging and 
spectra (Figs. 3(d) and 3(f)) both indicate low blue/green emission. Clinical impression of the 
site (solid circle) was “abnormal high risk” and graded “severe dysplasia” by histopathology. 
Figures 3(b) and 3(e) show images of a leukoplakia on the right lateral tongue. 
Autofluorescence results again indicated low blue/green emission. Clinical impression of the 
site (dashed circle) was “abnormal low risk,” however, histopathological diagnosis graded the 
site as “moderate dysplasia.” 
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 Fig. 2. Spectral imaging from the tongue of one patient with erythroplakia. (a, d) show the right 
ventral tongue in reflectance and autofluorescence modes, respectively, which had a clinical 
impression of “normal.” A biopsy (solid circle) indicated normal epithelium. (b, e) show an 
erythroplakia on the right dorsal tongue, which had a clinical impression of “abnormal high 
risk.” A biopsy (dotted circle) indicated squamous cell carcinoma. Reflectance spectra (c) 
contain characteristic oxy-hemoglobin peaks. Autofluorescence images and spectra from the 
biopsy region (f) show loss of blue fluorescence in the abnormal site. 
 
Fig. 3. Spectral imaging from one patient with multiple lesions. (a, d) show an erythroplakia on 
the right anterior floor of mouth, which had a clinical impression of “abnormal high risk.” A 
biopsy (solid circle) indicated severe dysplasia. (b, e) show a leukoplakia on the right lateral 
tongue, which had a clinical impression of “abnormal low risk.” A biopsy (dotted circle) 
indicated moderate dysplasia. (c, f) show the IMS reflectance and autofluorescence spectra, 
respectively, from the circled ROIs. 
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3.4 Spectral measurements 
Spectral trends from IMS measurements were analyzed by categorizing spectra based on 
clinical impression and histopathological diagnosis. First, a region of interest for each biopsy 
site (i.e. white circle in Figs. 2 and 3) was selected on the reflectance true-color images by the 
surgeon. The average autofluorescence and reflectance spectra were then calculated for pixels 
contained within the biopsy region. Next, a pathologist classified each biopsy according to the 
worst pathological grade; in cases where a biopsy and surgical specimen were obtained, the 
worst pathological grade was selected. Finally, the spectra from biopsy sites of three 
histopathological grades (normal, dysplasia, and cancer) were averaged. Figure 4 (“Snapshot 
Spectral Imaging”) presents average spectra for non-keratinized biopsy sites for the three 
histopathological diagnoses. The average autofluorescence spectra of abnormal tissue show an 
overall decrease in intensity and a relative decrease in blue/green intensity. An increase in 
relative red intensity is also apparent. Keratinized biopsy sites show a much larger increase in 
red fluorescence, which is most likely caused by porphyrins in bacteria colonizing the tissue 
(for example, see Fig. 6(b)) [15]. Reflectance spectra show characteristic hemoglobin 
absorption features, and can be used for specialized classification techniques, as shown in the 
following section. 
 
Fig. 4. Comparison of average spectra for different histopathological diagnoses. Data is shown 
for snapshot spectral imaging (left) and point spectroscopy from a previous clinical trial of 408 
sites (right). All sites were nonkeratinized. 
Figure 4 (“Point Spectroscopy”) shows the average autofluorescence spectra from a point 
spectrometer for qualitative comparison [7]; these measurements represent the average spectra 
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obtained from 408 non-keratinized sites in a previous clinical study, categorized by 
histopathological diagnosis. In this data, the excitation wavelength for fluorescence 
measurements with the point spectrometer was 410 nm and the tissue was measured with a 
contact probe. By comparison, autofluorescence data from the IMS was obtained with a 405 
nm LED and in a widefield imaging mode. The IMS spectra resemble spectra from the depth-
sensitive point spectrometer’s deep channel more than the shallow or medium channel (not 
shown), which suggests the IMS acquires autofluorescence from throughout the epithelium 
and stroma. IMS spectra may differ from point spectrometer spectra because of the IMS’s 
lower spectral resolution and sampling, inherent differences in light illumination/collection 
geometry in each device, and different illumination wavelengths. A thorough characterization 
of the spectral accuracy and shape from IMS data is shown in [23]. 
3.5 Spectral image analysis 
In addition to visualizing true-color images and individual spectra, the spatial-spectral 
datacube from the snapshot imaging spectrometer can be used for more advanced data 
analysis. For example, Fig. 5(a) shows reflectance spectral images from the lower lip of a 
normal volunteer, where vascularity patterns can be visualized at different depths 
corresponding to wavelength. This effect is caused by the dependence of wavelength on light 
penetration depth into tissue. While a similar affect was shown in [15], here the full data set is 
coregistered and obtained in 100 ms. Although we do not examine vascularity patterns with 
respect to pathological diagnosis in this manuscript, Edelstein et al. showed that oral vascular 
density is an important biomarker for some types of cancer [24]. 
 
Fig. 5. (a) Spectral imaging from the lower lip of a normal volunteer. The snapshot reflectance 
datacube can be used to visualize vasculature of different sizes and depths. (b) Spectral 
unmixing can be used to increase contrast of vasculature in the image. 
Another type of analysis that utilizes a spatial-spectral datacube is called spectral image 
processing. Standard image processing can identify texture, morphology, or RGB color 
features in order to determine a region of interest. In addition to these features, spectral image 
processing enables multi-dimensional and spectral analysis algorithms [25]. One technique, 
called spectral linear unmixing, can be used to computationally separate relative contributions 
of reference spectra in a datacube. In Fig. 5(b), an average measured spectrum for blood 
vessels was used with spectral linear unmixing to highlight vascularity with a green overlay. 
In Fig. 6, spectral image processing was used to automatically identify suspicious regions of 
interest in two sites of invasive carcinoma. First, an average reflectance spectrum was 
determined for all biopsy sites in the pilot study. Next, the linear correlation coefficient was 
calculated for every x-y coordinate in a given reflectance datacube with respect to the 
reference spectra. The result was then used to automatically highlight oral mucosa and skin. 
Figures 6(c) and 6(f) (white line) show the boundary of regions with a correlation coefficient 
> 0.98, which effectively delineates tissue regions. The algorithm performed similarly for 
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other images in the data set. Abnormal tissue was identified by thresholding the blue region 
(475 – 485 nm) of normalized autofluorescence spectra. Figures 6(c) and 6(f) (red line) show 
the boundary of tissue identified as abnormal. 
 
Fig. 6. Spectral imaging from two patients with invasive carcinoma. Although the lesion in (a, 
d) is clearly visible, loss of autofluorescence in (b, e) shows boundaries not as apparent with 
traditional white light imaging. Spectral analysis (c, f) was used to determine the tissue region 
(white line) with areas of reduced autofluorescence highlighted (red line). 
4. Discussion 
The results from this study demonstrate diagnostic features obtained with a snapshot imaging 
spectrometer with potential clinical utility for diagnosis and management of oral cancer and 
precancer. In addition to acquiring color images and individual spectra, snapshot spectral 
imaging can enable real-time spectral analysis over an entire tissue region with high spatial 
resolution, extending the diagnostic potential of that reported from other optical devices used 
in the oral cavity [7,13,16]. Several applications in remote sensing have proved that spectral 
imaging can be used for more selective classification than with standard imaging alone [26]. 
In this study, we acquired spectral data in real-time and showed that offline spectral image 
analysis can be used for linear unmixing, correlation spectroscopy, and spectral thresholding 
[18,20,23]. Results from this pilot study also show that real-time spectral data acquisition is 
feasible for in vivo oral cancer imaging (Fig. 6). In the future, we plan to implement real-time 
spectral analysis for oral cancer diagnostics. Such analysis was not previously possible 
because spectral imaging devices typically suffer from low speed, low light-throughput, 
and/or motion artifacts. A larger clinical study will determine the most significant spectral 
bands in autofluorescence and reflectance for widefield disease classification, and estimate 
the sensitivity and specificity for lesion characterization in different clinical populations. 
Snapshot spectral imaging devices will also play a vital role for emerging optical 
modalities that require spatial-spectral information. For example, Cuccia et al. developed a 
modulated imaging technique that requires several spectral samples from a reflectance image. 
Using the spectral images and a Monte Carlo model, the scattering and absorption coefficients 
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in tissue can be determined in vivo [27,28]. Previously, modulated imaging was performed 
with scanning spectral filters or computed tomography [29], which required long exposure 
times or slow image reconstruction, respectively. Preliminary studies have shown that 
modulated imaging with our image mapping spectrometer can obtain diffuse reflectance, 
absorption coefficient, and reduced scattering coefficient in tissue [19]. These properties have 
been related to classification features for oral cancer diagnostics [8]. In the future, the 
combination of snapshot spectral imaging with new optical modalities could provide novel 
diagnostic techniques for oral cancer. 
Finally, this work demonstrates that multimodal spectral imaging (i.e. reflectance and 
autofluorescence) can be used for combined spectral analysis in the oral cavity. As a proof of 
concept, we used correlation analysis of the reflectance spectra to segment tissue within the 
image, and then the autofluorescence spectra to highlight suspicious regions. Another type of 
spectral analysis, linear unmixing, was used with our imaging spectrometer to extract relative 
oxy/deoxy-hemoglobin concentrations and tissue oxygenation from reflectance measurements 
of the skin [23]. Ongoing studies aim to extract a full set of tissue properties, including: 
autofluorescence features (i.e. collagen breakdown and porphyrin content), reflectance 
features (i.e. oxy/deoxy-hemoglobin content and oxygen saturation), and diffuse features (i.e. 
scattering and absorption) over the entire oral cavity in vivo. 
5. Conclusion 
We report on the development and initial clinical testing of a novel device for point-of-care 
oral cancer diagnostics. The study demonstrates simultaneous acquisition of spatial-spectral 
tissue properties over 5 cm
2
 in autofluorescence or reflectance modes. In the future, clinical 
studies with increased patient size and in combination with additional optical modalities may 
enable non-invasive detection of oral malignancies with improved sensitivity and specificity. 
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